Capricor Therapeutics is trading 10% down at $8.05; the specific reason for the decline remains unclear. - On October 5, the company announced positive HOPE-3 open-label extension data, including a reported 76% reduction in upper-limb decline after placebo patients switched to Deramiocel. - The company said the data were included in its BLA amendment; the FDA decision is targeted for November 22, 2026. - Broader indices were higher, and available reporting does not confirm a direct catalyst.